The prognostic impact of O 6-methylguanine DNA methyltransferase and epidermal growth factor receptor expressions on primary gliosarcoma: A clinicopathologic and immunohistochemical study of seven cases at a single institution

Indian Journal of Pathology and Microbiology

Volumn 54, Issue 4, 2011, Pages 683-687

  Lin, Jui Wei ^a   Wu, You Ting ^a   Chang, I Wei ^a,b  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b I SHOU UNIVERSITY   (Taiwan)

Author keywords

Epidermal growth factor receptor; gliosarcoma; O 6 methylguanine DNA methyltransferase

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; DNA METHYLTRANSFERASE; MGMT PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; GLIOSARCOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; OVERALL SURVIVAL; PATHOLOGY; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME; AGED; CASE REPORT; EVALUATION; GENETICS; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; PROGNOSIS;

ADULT; AGED; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GLIOSARCOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84856403512     PISSN: 03774929     EISSN: 09745130     Source Type: Journal    
DOI: 10.4103/0377-4929.91491     Document Type: Article

References (35)

1. Prados MD, Russo C. Chemotherapy of brain tumors. Semin Surg Oncol 1998;14:88-95. (Pubitemid 128774939)
2. Silber JR, Bobola MS, Blank A, Schoeler KD, Haroldson PD, Huynh MB, et al. The apurinic/apyrimidinic endonuclease activity of Apel/Ref-1 contributes to human glioma cell resistance to alkylating agents and is elevated by oxidative stress. Clin Cancer Res 2002;8:3008-18. (Pubitemid 35025751)
3. Ludlum DB. DNA alkylation by the haloethylnitrosoureas: Nature of modifications produced and their enzymatic repair or removal. Mutat Res 1990;233:117-26. (Pubitemid 20379149)
4. 6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas. Clin Cancer Res 2005;11:5167-74. (Pubitemid 41003702)
5. 6-alkylguanine-DNA alkyltransferase analysis and response to Temodol in newly diagnosed malignant glioma. J Clin Oncol 1998;16:3851-7. (Pubitemid 29001538)
6. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003. (Pubitemid 40349502)
7. Uhm JH, Ballman KV, Wu W, Giannini C, Krauss JC, Buckner JC, et al. Phase II evaluation of gefitinib in patients with newly diagnosed grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074. Int J Radiat Oncol Biol Phys 2011;80:347-53.
8. Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, et al. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol 2010;12:95-103.
9. 6-methylguanine-DNA methyltransferase gene. Cancer Res 1997;57:3672-7. (Pubitemid 27381206)
10. 6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene. Mol Cell Biol 1997;17:5612-9. (Pubitemid 27357657)
11. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999;59:793-7. (Pubitemid 29086728)
12. 6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol 1995;51:167-223.
13. 6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: A Southwest Oncology Group study. J Clin Oncol 1998;16:3310-5. (Pubitemid 28481626)
14. 6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: Frequency and time to tumor progression after alkylating agent-based chemotherapy. Clin Cancer Res 1999;5:807-14. (Pubitemid 29180832)
15. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343:1350-4.
16. 6-methylguanine DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma. J Neurooncol 2008;87:71-8.
17. Prados MD, Chang SM, Butowski N, DeBoer R, Parvataneni R, Carliner H, et al. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol 2009;27:579-84.
18. 6-methylguanine DNA methyltransferase status determined by promoter methylation and immunohistochemistry in gliosarcoma and their clinical implications. J Neurooncol 2011;101:477-86.
19. Lund-Johansen M, Bjerkvig R, Humphrey PA, Bigner SH, Bigner DD, Laerum OD. Effect of epidermal growth factor receptor on glioma cell growth, migration, and invasion in vitro. Cancer Res 1990;50:6039-44. (Pubitemid 20331419)
20. Fuller GN, Bigner SH. Amplified cellular oncogenes in neoplasms of the human central nervous system. Mutat Res 1992;276:299-306.
21. Wikstrand CJ, Reist CJ, Archer GE, Zalutsky MR, Bigner DD. The class III variant of the epidermal growth factor receptor (EGFRvIII): Characterization and utilization as an immunotherapeutic target. J Neurovirol 1998;4:148-58. (Pubitemid 28167490)
22. Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK, et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA 1994;91:7727-31.
23. Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS, et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 1992;89:2965-9.
24. Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004;22:133-42.
25. Das P, Puri T, Jha P, Pathak P, Joshi N, Suri V, et al. A clinicopathological and molecular analysis of glioblastoma multiforme with long-term survival. J Clin Neurosci 2011;18:66-70.
26. Tohma Y, Gratas C, Biernat W, Peraud A, Fukuda M, Yonekawa Y, et al. PTEN (MMAC) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J Neuropathol Exp Neurol 1998;57:684-9. (Pubitemid 28335057)
27. Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996;6:217-23.
28. Hatanpaa KJ, Burma S, Zhao D, Habib AA. Epidermal growth factor receptor in glioma: Signal transduction, neuropathology, imaging, and radioresistance. Neoplasia 2010;12:675-84.
29. Reis RM, Konu-Lebleblicioglu D, Lopes JM, Kleihues P, Ohgaki H. Genetic profile of gliosarcomas. Am J Pathol 2000;156:425-32. (Pubitemid 30643797)
30. Actor B, Cobbers JM, Büschges R, Wolter M, Knobbe CB, Lichter P, et al. Comprehensive analysis of genomic alterations in gliosarcoma and its two tissue components. Genes Chromosomes Cancer 2002;34:416-27. (Pubitemid 34787463)
31. Stroebe H. Uber Entstehung und Bau der Hirngliome. Beitr Pathol Anat 1895;18:405-86.
32. Burger PC, Scheithauer BW. Tumors of the central nervous system. 4 th Series. Fascicle 7. Washington: Armed Forces Institute of Pathology; 2007.
33. Meis JM, Martz KL, Nelson JS. Mixed glioblastoma multiforme and sarcoma: A clinicopathologic study of 26 radiation therapy oncology group cases. Cancer 1991;67:2342-9.
34. Biernat W, Aguzzi A, Sure U, Grant JW, Kleihues P, Hegi ME. Identical mutation of the p53 tumor suppressor gene in the gliomatous and sarcomatous components of gliosarcomas suggest a common origin from glial cells. J Neuropathol Exp Neurol 1995;54:651-6.
35. Boerman RH, Anderl K, Hearth J, Borell T, Johnson N, Schaeffer-Klein J, et al. The glial and mesenchymal elements of gliosarcomas share similar genetic alterations. J Neuropathol Exp Neurol 1996;55:973-81. (Pubitemid 126449411)